Home › Chronic Inflammatory Demyelinating Polyradiculoneuropathy › NCT07264426

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Aged ≥18 years at time of providing informed consent
* Diagnosed with CIDP
* Planned to be receiving efgartigimod treatment within the CIDP treatment label of efgartigimod in the participant's respective country
* Efgartigimod treatment-naïve at time of screening

Exclusion Criteria:

* Polyradiculoneuropathy due to any other cause(s)
* Current participation in any interventional clinical study at time of screening, or planned participation before initiation of efgartigimod

About the study

The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod.

As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care.

Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.

What is being tested

• Efgartigimod PH20 SC (biological)

Sponsor: argenx · Participants: 200 · Started: Aug 11, 2025

Contact the study team

• Sabine Coppieters, MD · Phone: 857-350-4834

Official record on ClinicalTrials.gov — NCT07264426

Locations in the U.S.

Conditions

• Chronic Inflammatory Demyelinating Polyradiculoneuropathy

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.